Welcome to our dedicated page for Enlivex Ltd. SEC filings (Ticker: ENLV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enlivex Ltd.’s SEC filings document its status as an Israeli foreign private issuer with ordinary shares listed under ENLV, its clinical-stage Allocetra™ program, and its prediction markets treasury strategy centered on the RAIN token and Rain protocol.
Recent Form 6-K reports furnish current disclosures on regulatory clearances for Allocetra™ in age-related knee osteoarthritis, annual financial results, tokenized representations of the company’s ordinary shares, Rain protocol ecosystem updates, senior secured convertible debt, and the completed corporate name change from Enlivex Therapeutics Ltd. to Enlivex Ltd. The filings also reference registration statements and governance records tied to shareholder approvals and capital structure.
Enlivex Ltd. is registering for resale up to 10,000,000 ordinary shares that may be sold from time to time by the holder of its Senior Secured Convertible Promissory Note, without Enlivex receiving any proceeds from these sales. The shares are issuable under a $21.0 million note issued in a March 23, 2026 private placement for an aggregate purchase price of $19.0 million. The note matures on March 23, 2027, is senior secured, does not bear interest unless in default when a 10.0% annual rate applies, and is repayable in nine monthly principal installments of approximately $2.3 million, in cash, shares, or a combination. The note is convertible at an initial price of $40.37625 per share and may be prepaid at 105% of outstanding principal or, upon certain events of default, be put back to Enlivex at 110% of outstanding principal. Enlivex’s ordinary shares trade on the Nasdaq Capital Market under the symbol ENLV, with 17,485,462 shares outstanding as of August 5, 2026, and a last reported price of $1.84 per share on August 12, 2026.
Lind Global Asset Management XIV, LLC, together with The Lind Partners, LLC and Jeff Easton, reports beneficial ownership of ordinary shares of Enlivex Ltd. through a Senior Secured Convertible Promissory Note. The Note is convertible into ordinary shares but is subject to a 9.99% beneficial ownership limitation, so conversions cannot increase their stake above 9.99% of Enlivex’s ordinary shares.
Each Reporting Person is listed with 1,927,744 ordinary shares beneficially owned, representing 9.99% of the class, with sole voting and dispositive power over these shares. Jeff Easton, as managing member of The Lind Partners, may be deemed to share voting and dispositive power over the shares held by Lind Global Asset Management XIV, LLC, while disclaiming beneficial ownership except to the extent of his pecuniary interest.
Enlivex Ltd. amended its Senior Secured Convertible Promissory Note originally issued for $21.0 million to Lind Global Asset Management XIV, LLC. The amendment removes the event of default tied to market capitalization staying below $75.0 million for ten consecutive trading days, and the investor waived the prior default under that provision.
The remaining principal outstanding was increased from approximately $16.3 million to $19.2 million, with monthly payments reduced from about $2.3 million to $1.2 million and the maturity date extended until full repayment, subject to possible monthly payment waivers by the holder. Interest of 10.0% per annum now accrues for each day the company’s market capitalization is below $75.0 million. The holder may convert the note into ordinary shares at the lower of $40.37625 or 80% of the average of the three lowest daily volume weighted average prices over the 20 trading days before a conversion notice. For six months after the amendment date, Enlivex may prepay the note at a reduced 2.5% cash premium instead of 5.0%.
Enlivex Ltd., an Israel-based clinical-stage immunotherapy and “quality longevity” company, has filed a Form F-3 to register for resale up to 10,000,000 ordinary shares. These shares may be sold from time to time by Lind Global Asset Management XIV, LLC, the selling shareholder under a previously issued Senior Secured Convertible Promissory Note.
The Note has an aggregate principal amount of $21.0 million, for which Enlivex received $19.0 million in a March 23, 2026 private placement, and is convertible at an initial price of $40.37625 per share, with additional shares potentially issued as repayment shares tied to trading prices. Enlivex will not receive any proceeds from the resale of these shares, though it will bear the registration expenses. As of August 5, 2026, 17,485,462 ordinary shares were outstanding, and the company’s stock traded on Nasdaq Capital Market under “ENLV” at $2.18 per share.
Enlivex Ltd. reported that trading volume on the Rain protocol reached $860 million as of July 29, 2026, representing 622% month-over-month growth in July versus June. The Rain protocol underpins Enlivex’s prediction markets–driven digital asset treasury strategy.
According to the Rain Foundation, target Rain protocol trading volumes are expected to rise to $1.3 billion in 2027, $12 billion in 2028 and $33 billion in 2029, with associated net fees allocated to buy-and-burn the RAIN token of $24 million, $216 million and $600 million, respectively.
Enlivex Ltd., an Israel-based longevity company, plans a live investor webinar on July 30, 2026, at 10:00 AM Eastern Time. Management intends to discuss the rationale and intended use of proceeds for a recently announced private placement, the status and strategy of its RAIN protocol-based treasury, and recent clinical progress for its Allocetra™ immunotherapy program.
The agenda covers Enlivex’s prediction markets treasury built around the Rain protocol, including recent milestones and portfolio roadmap, and a clinical update on the ongoing Phase 2b trial of Allocetra™ in age-related knee osteoarthritis. Allocetra™ has recently received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for treating symptomatic knee osteoarthritis in patients aged 64 and older. Forward-looking statements address expectations and risks related to the transaction, the digital asset treasury strategy and RAIN token market dynamics, and future clinical and regulatory outcomes.
Enlivex Ltd. entered into a Securities Purchase Agreement with the Rain Foundation for a private placement of up to $400,000,000 of ordinary shares or pre-funded warrants. The purchase price is $5.00 per share ($4.999 per pre-funded warrant) when paid in U.S. dollars, USDT or USDC, and $6.00 per share ($5.999 per pre-funded warrant) when paid in RAIN tokens. Rain has currently elected to fund the purchase using RAIN tokens but may switch to cash or stablecoins before closing.
Each pre-funded warrant is immediately exercisable at $0.001 per ordinary share, has no expiration and is subject to a beneficial ownership limitation that cannot exceed 24.9%. Enlivex also obtained a put option allowing it, at its discretion, to require Rain to purchase up to an additional $400,000,000 of equity securities at the same prices during a period of up to 36 months from closing, subject to earlier termination events.
Rain agreed not to transfer the acquired securities until 20% are released when the resale registration statement becomes effective and the remaining 80% are released ratably on a daily basis over six months starting six months after that date. Closing requires shareholder approval under Israeli law and Nasdaq rules. Enlivex plans to use substantially all net proceeds paid in dollars or stablecoins to acquire RAIN tokens, support its digital asset treasury strategy, pay transaction costs and repay indebtedness, while any RAIN proceeds will be held in dedicated treasury wallets. A registration rights agreement will require Enlivex to register the resale of the shares and warrant shares until Rain has sold them or can rely on Rule 144.
Enlivex Ltd. entered into a securities purchase agreement with a single institutional investor for a private placement of $400,000,000 of ordinary shares (or equivalents). Shares will be priced at $5.00 when funded in U.S. dollars, USDT or USD Coin, and $6.00 when funded in RAIN tokens, representing premiums of 17.4% and 40.8% to the July 27, 2026 closing price, for expected gross proceeds of approximately $400,000,000 before expenses.
The investor has currently elected to fund the purchase price using RAIN tokens, an election that may change before closing. Enlivex plans to use net proceeds to further its prediction markets treasury strategy built around the Rain protocol and to continue advancing Allocetra™, its clinical-stage immunotherapy for age-related osteoarthritis.
The agreement also grants Enlivex a discretionary right, exercisable over 36 months after closing, to require the investor to purchase up to an additional $400,000,000 of ordinary shares on the same pricing terms. Closing and the put right are subject to shareholder approval under Nasdaq Listing Rules 5635(a) and 5635(b) and Section 274 of the Israeli Companies Law.
Enlivex Ltd. reported an update on its digital asset treasury built around the RAIN token. As of July 18, 2026, net asset value per ordinary share was $66.16, and the company held 79,550,593,122 RAIN tokens with a total value of approximately $1.1 billion. Updated unaudited, mark-to-market treasury metrics are available on its public dashboard.
Enlivex describes itself as a quality longevity company advancing Allocetra, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. Alongside this clinical portfolio, it operates a prediction markets treasury strategy using the Rain protocol on Arbitrum, combining therapeutic development with exposure to the emerging prediction markets ecosystem. The company notes that expectations regarding its digital asset strategy, RAIN token markets, and clinical and regulatory outcomes involve significant risks and uncertainties.